Latest news

• More waiting for Allergan and Gedeon Richter's antipsychotic

  The drug is one of several new antipsychotic agents expected to drive growth in the schizophrenia market in the coming years, along with Johnson &Johnson's three-monthly paliperidone palmitate depot,

• FDA approves J&J’s schizophrenia drug Invega Trinza

  The FDA has approved Johnson &Johnson's Invega Trinza (three-month paliperidone palmitate) for schizophrenia. ... Before patients can be started on the drug they must first be taking Janssen's Invega Sustenna, a one-month form of paliperidone palmitate,

• J&J gets quicker review for schizophrenia depot in US

  The US FDA has granted priority review status to Johnson &Johnson's paliperidone palmitate depot, which if approved will become the first schizophrenia drug that can be administered just four times ... The current formulation of paliperidone - sold as

• Double win for J&J's schizophrenia franchise

  Added to that, the pharma company has just stopped a trial of its three-monthly formulation of Risperdal (risperidone) follow-up paliperidone palmitate on positive results, setting up a filing later ... Three-monthly paliperidone. Meanwhile, J&J could

• OTC recovery helps J&J in first-quarter

  The company said the sales increase was also helped by new pharmaceutical product introductions, including its depot antipsychotic Invega Sustenna/Xeplion (paliperidone palmitate), which grew 76 per cent to $284m in